Skip to main navigation

Work With Us
Contact

Home
About Us
Science
- Publications
Pipeline
UBX1325
Clinical Trials
Investors & Media
Work With Us
Contact
Menu

Investors & Media

Corporate Overview
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
- Contact IR
- Investor FAQs

Investor Tools

Print Page
Email Page
Contact IR
Email Alerts
RSS Feeds

Company Overview

UNITY Biotechnology is developing transformative medicines by leveraging fundamental pathways of aging biology, with a focus in retinal diseases.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Corporate Presentation

Download

Upcoming Events

More events are coming soon.

Key Data Presentations

Ophthalmology Day Webcast Presentation

Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up

ARVO 2024, Presented by Dante Pieramici, M.D.

View More

Latest Press Releases

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

November 4, 2024

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

September 24, 2024

View More

In The News

How to kill the ‘zombie’ cells that make you age

May 15, 2024

UNITY Biotech’s CEO on data that builds conviction and pioneering novel treatment paradigms

May 10, 2023

A Drug to Treat Aging May Not Be a Pipe Dream

January 1, 2023

Is longevity more than a billionaire’s pipe-dream?

March 15, 2022

Shooting for longevity and the stars

October 14, 2021

Can Destroying Senescent Cells Treat Age-Related Disease?

March 1, 2020

10 Breakthrough Technologies

February 26, 2020

©2024 Unity Biotechnology. All Rights Reserved.

Terms & Conditions |
Privacy Policy